MedTrace Logo

Energy Metabolism and Acute Effects of Protein Diets in Metabolically Obese Normal Weight Individuals

NCT06802341 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-01-31

No results posted yet for this study

Summary

Asians tend to develop type 2 diabetes (T2D) at lower body mass index (BMI) levels and younger ages compared to other populations. This leads to a longer duration of suffering from long-term complications associated with the disease, ultimately resulting in shorter life expectancy. Notably, approximately 40% of newly diagnosed T2D cases in Asians occur in individuals considered lean, with a BMI reported to be less than 22 kg/m2. This phenomenon is termed the "Metabolically Obese Normal Weight" (MONW) phenotype. MONW individuals are characterized as having a normal body weight but exhibiting obesity-related metabolic disturbances, including excess body fat with ectopic fat deposition, insulin resistance, and dyslipidemia.

Conditions

  • Healthy
  • Glucose Metabolism Disorders
  • Obesity, Visceral
  • Obesity; Endocrine
  • Insulin Sensitivity
  • Insulin Resistance

Interventions

OTHER

Normal protein diet

Animal-based protein meal plan consisted of 60% carbohydrates, 10% proteins and 30% lipids

OTHER

Animal protein diet

Animal based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids

OTHER

Plant based diet

Plant based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids

Sponsors & Collaborators

  • Singapore Institute of Food and Biotechnology Innovation

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06802341 on ClinicalTrials.gov